Author

S. de Brot

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 2 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:human· 3 Organism:mouse· 3 Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Assay:proteomics· 2 Research Focus:cancer & tumor microenvironment· 1

Frequent Co-Authors

M. A. Rubin· 2 shared M. F. Bachmann· 2 shared M. O. Mohsen· 2 shared M. Vogel· 2 shared A. Benjak· 1 shared A. Califano· 1 shared A. King-Yung Leung· 1 shared A. Mitrofanova· 1 shared

Activity by Year

2020-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 15 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

M. A. Rubin

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

A double-negative prostate cancer subtype is vulnerable to SWI/SNF-targeting degrader molecules

P. D. Thienger, I. Paassen, X. Yao, P. D. Rubin, M. Lehner, N. Lillis, A. Benjak, S. Shah, A. King-Yung Leung, S. de Brot, A. Naveed, B. Daniel, M. Shi, J. Tremblay, J. Triscott, , M. A. Rubin

This study identifies a SWI/SNF-targeting therapy effective against a double-negative prostate cancer subtype, showing it reduces viability in both AR-dependent and WNT-dependent models.

bioRxiv · Mar 24, 2024Cancer Biology

OncoLoop: A network-based precision cancer medicine framework

A. Vasciaveo, M. Zou, J. M. Arriaga, F. Geraldes de Almeida, E. F. Douglass, M. Shibata, A. Rodriguez-Calero, S. de Brot, A. Mitrofanova, C. W. Chua, C. Karan, R. Realubit, S. Y. Pampou, J. Y. Kim, E. Corey, , C. Abate-Shen

OncoLoop predicts and validates drug sensitivity in tumors and their models by leveraging perturbational profiles of oncology drugs, showing success in prostate cancer models and patient cohorts.

bioRxiv · Feb 11, 2022Cancer Biology

Bedside formulation of a personalized multi-neoantigen vaccine against mammary carcinoma

M. O. Mohsen, D. E. Speiser, J. Michaux, H. Pak, B. J. Stevenson, M. Vogel, V. P. Inchakalody, S. de Brot, G. Coukos, S. Dermime, M. Bassani-Sternberg, M. F. Bachmann

This paper develops a personalized multi-neoantigen vaccine using long peptides linked to virus-like particles, showing improved anti-tumor effects in a murine mammary carcinoma model.

bioRxiv · Apr 24, 2021Immunology

SARS-CoV-2 spike D614G variant confers enhanced replication and transmissibility

B. Zhou, T. T. N. Thao, D. Hoffmann, A. Taddeo, N. Ebert, F. Labroussaa, A. Pohlmann, J. King, J. Portmann, N. J. Halwe, L. Ulrich, B. S. Trueb, J. N. Kelly, X. Fan, B. Hoffmann, , M. Beer

This study shows the SARS-CoV-2 D614G variant has enhanced replication and transmissibility in animal models, explaining its global dominance.

bioRxiv · Oct 27, 2020Microbiology

The impact of size on particle drainage dynamics and antibody response

S. Zinkhan, A. Ogrina, I. Balke, G. Resevica, A. Zeltins, S. de Brot, C. Lipp, X. Chang, L. Zha, M. Vogel, M. F. Bachmann, M. O. Mohsen

This study compares the draining kinetics and immunogenicity of round and rod-shaped VLPs, finding that round VLPs are more effective in antigen presentation and induce stronger immune responses.

bioRxiv · Sep 28, 2020Immunology